Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
nelarabine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| nelarabine | DRUG | - |
DISEASE CHARACTERISTICS: Diagnosis of refractory chronic lymphocytic leukemia Evidence of active disease after fludarabine or alkylator therapy Must meet one or more of the following criteria for active disease: Minimum of one of the following disease-related symptoms: Weight loss of 10% or more wit...
Top 20 of 63 competitors
Nelarabine/m2 is an investigational small molecule being studied for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. It is also being evaluated in chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents. The drug is in clinical development for these oncology indications.
Nelarabine/m2 is being developed by GSK plc, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with certain types of leukemia and lymphoma.
Nelarabine/m2 is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities. It is still undergoing clinical evaluation to determine its safety and effectiveness.
Nelarabine/m2 has been studied in two completed clinical trials. NCT00003635 was a Phase 2 study in patients with chronic lymphocytic leukemia that had not responded to fludarabine or alkylating agents. NCT00406757 was a Phase 1 study in Japanese patients with leukemia or lymphoma, enrolling 13 participants.
Yes, Nelarabine/m2 is also known as 506U78. Clinical trial records refer to the drug by both names, with studies titled '506U78 in Treating Patients With Chronic Lymphocytic Leukemia' and 'Clinical Evaluation of Nelarabine (506U78) in Japanese Patients With Leukemia or Lymphoma'.